Amishi Y. Shah, M.D.

Peer-Reviewed Articles

1. Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus None(None):None, 2024. PMID: 39307587.
2. Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun 4(9):2444-2453, 2024. PMID: 39207194.
3. Zhang T, Tan A, Shah AY, Iyer G, Morris V, Michaud S, Sridhar SS. Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma. Oncologist None(None):None, 2024. PMID: 39167703.
4. Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist 29(7):589-595, 2024. e-Pub 2024. PMID: 38478923.
5. Lagana M, Balderrama-Brondani V, Herrera KR, Chahla B, Yaylaci F, Bassett RL, Jimenez C, Varghese J, Waguespack SG, Campbell MT, Shah AY, Rojas Hernandez CM, Habra MA. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist 29(7):575-580, 2024. PMID: 38776552.
6. Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw 22(5):1-8, 2024. e-Pub 2024. PMID: 38190801.
7. Matin SF, Adibi M, Shah AY, Alhalabi O, Corn P, Guo C, Amirtharaj R, Xiao L, Lange S, Duose DY, Wang S, Pal S, Campbell MT. Phase 1b Trial Evaluating Tolerability and Activity of Targeted FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma. J Urol 211(6):101097JU0000000000003928, 2024. e-Pub 2024. PMID: 38573872.
8. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2023. PMID: 38035767.
9. Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suarez C, Porta C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, George S, Scheffold C, Wang P, Fedorov V, Motzer RJ, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open 9(5):102994, 2024. e-Pub 2024. PMID: 38642472.
10. Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, Shah AY, Long JP, Zhang M, Ochieng J, Haymaker C, Habra MA. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol 25(5):649-657, 2024. PMID: 38608694.
11. Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Chahla BB, Varghese J, Jimenez C, Waguespack SG, Graham PH, Perrier ND, Fisher SB, Karam JA, Shah AY, Campbell M, Hassan MM, Habra MA. Incidence and geographical distribution of adrenocortical carcinoma: Retrospective analysis of a state cancer registry. Endocr Pract 30(1):25-30, 2024. e-Pub 2023. PMID: 37858722.
12. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
13. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol 118(9):1609-1617, 2023. e-Pub 2023. PMID: 37307533.
14. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 9(5):734-741, 2023. e-Pub 2023. PMID: 36863962.
15. Saji A, Chopra M, Jacob J, Altan M, Alhalabi O, Shah AY, Qiao W, Wang Y, Thomas A. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis. J Cancer Res Clin Oncol 149(9):1-12, 2023. e-Pub 2022. PMID: 36585982.
16. Liu C, Amin R, Shatila M, Short N, Altan M, Shah A, Alhalabi O, Okhuysen P, Thomas AS, Wang Y. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J Cancer Res Clin Oncol 149(7):3965-3976, 2023. e-Pub 2022. PMID: 36030431.
17. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684, 2023. e-Pub 2023. PMID: 37164948.
18. Singh AP, O'Brien BJ, Bloundeau CE, Flowers CR, Morris VK, Shah AY. Association of emotional exhaustion with career burnout among early-career medical oncologists: a single-institution study. JCO Oncology Practice 20(1):137-144, 2023. PMID: 37235818.
19. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2021. PMID: 34789422.
20. Moore JA, Lehner MJ, Anfossi S, Datar S, Tidwell RS, Campbell M, Shah AY, Ward JF, Karam JA, Wood CG, Pisters LL, Calin GA, Tu SM. Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass 4(1):81-87, 2023. e-Pub 2022. PMID: 36569509.
21. Sherry AD, Bathala TK, Liu S, Fellman BM, Chun SG, Jasani N, Guadagnolo BA, Jhingran A, Reddy JP, Corn PG, Shah AY, Kaiser KW, Ghia AJ, Gomez DR, Tang C. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results from the Lead-In Phase of the Randomized Basket Trial EXTEND. Int J Radiat Oncol Biol Phys 114(5):910-918, 2022. e-Pub 2022. PMID: 35691448.
22. Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
23. Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 23(7):888-898, 2022. e-Pub 2022. PMID: 35688173.
24. De B, Venkatesan A, Msaouel P, Ghia A, Li J, Yeboa D, Nguyen Q, Bishop A, Jonasch E, Shah A, Campbell M, Wang J, Zurita-Saavedra A, Karam J, Wood C, Matin S, Tannir N, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU International 129(5), 2022. PMID: None.
25. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int 129(5):610-620, 2022. e-Pub 2021. PMID: 34228889.
26. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641):eabm6420, 2022. e-Pub 2022. PMID: 35442707.
27. Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients with Adrenocortical Carcinoma: A Multidisciplinary Referral Center Experience. J Clin Endocrinol Metab 107(5):1239-1246, 2022. e-Pub 2022. PMID: 35092681.
28. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
29. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
30. Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 20(2):176-182, 2022. e-Pub 2021. PMID: 35039231.
31. Moore, JA, Tidwell, R, Lehner, MJ, Campbell, M, Shah, AY, Zhang, M, Guo, CC, Ward, JF, Karam, JA, Wood, CG, Pisters, LL, Tu, S. Very Late Recurrence in Germ Cell Tumor of the Testis. Cancers 14(5), 2022. PMID: 35267435.
32. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2021. PMID: 34362693.
33. Alhalabi, O, Campbell, M, Xiao, L, Adriazola, AC, Wilson, NR, Siefker-Radtke, AO, Corn, P, Zurita-Saavedra, A, Jonasch, E, Gao, J, Adibi, M, Kamat, A, Navai, N, Pisters, LL, Dinney, CP, Matin, S, Shah, AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. PMID: 35475152.
34. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer 19(6):e401-e408, 2021. e-Pub 2021. PMID: 34625389.
35. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol 39(12):4345-4354, 2021. e-Pub 2021. PMID: 34370078.
36. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol 22(12):1732-1739, 2021. e-Pub 2021. PMID: 34717797.
37. Hahn AW, Shah AY, Campbell MT. First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials. None, 2021. PMID: None.
38. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34885132.
39. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 12(1):6375, 2021. e-Pub 2021. PMID: 34737281.
40. Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11), 2021. PMID: 34789551.
41. Alhalabi, Omar, Campbell, Matthew T, Xiao, Lianchun, Adriazola, Ana C, Wilson, Nathaniel R, Siefker-Radtke, Arlene O, Corn, Paul G, Zurita, Amado, Jonasch, Eric, Gao, Jianjun, Adibi, Mehrad, Kamat, Ashish M, Navai, Neema, Pisters, Louis L, Dinney, Colin, Matin, Surena F, Shah, Amishi Y. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass, 2021. PMID: None.
42. Tang C, Msaouel P, Kobayashi K, Shay AY, Choi S, Le V. Phase II Trial Investigating Definitive Radiation Therapy in lieu of Systemic Therapy for Oligometastatic Renal Cell Carcinoma. Lancet Oncology, 2021. PMID: None.
43. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
44. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
45. Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, ØK T, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 22(7):946-958, 2021. e-Pub 2021. PMID: 34143969.
46. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. PMID: 34326169.
47. Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist 26(6):476-482, 2021. e-Pub 2021. PMID: 33792094.
48. Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance and clinical outcomes. Cancer Med 10(7):2341-2349, 2021. e-Pub 2021. PMID: 33650321.
49. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9):2170, 2021. e-Pub 2021. PMID: 33946504.
50. McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer 127(6):840-849, 2021. e-Pub 2020. PMID: 33216356.
51. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ, Investigators C. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384(9):829-841, 2021. PMID: 33657295.
52. Viscuse P, Marques-Piubelli M, Heberton M, Cuentas E, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Curry J, Campbell MT. Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions from Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Frontiers in Oncology 11(11):621951, 2021. PMID: 33747934.
53. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2020. PMID: 33323389.
54. Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. Eur Urol Oncol 4(1):102-111, 2021. e-Pub 2019. PMID: 31786162.
55. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2020. PMID: 33187886.
56. Zou F, Abu-Sbeih H, Ma W, Peng Y, Qiao W, Wang J, Shah AY, Glitza Oliva IC, Piha-Paul SA, Thompson JA, Zhang HC, Thomas AS, Wang Y. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. J Natl Compr Canc Netw 19(6):700-709, 2020. e-Pub 2020. PMID: 33316767.
57. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
58. Alhalabi O, Campbell M, Shah A, Siefker-Radtke A, Gao J. Emerging treatments in advanced urothelial cancer. Curr Opin Oncol 32(3):232-239, 2020. PMID: 32209822.
59. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis. Oncologist 25(3):252-258, 2020. e-Pub 2019. PMID: 32162795.
60. Yeboa DN, Shah AY. Managing Perplexing Intracranial Lesions. Int J Radiat Oncol Biol Phys 105(2):244, 2019. PMID: 31492380.
61. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67-75, 2019. e-Pub 2019. PMID: 31075726.
62. Lemke EA, Shah AY, Campbell M, Tannir NM. Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis. J Adv Pract Oncol 10(4):333-339, 2019. e-Pub 2019. PMID: 33343982.
63. Alhalabi O, Rafei H, Shah AY, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Current Opinion in Oncology 31(3):207-215, 2019. PMID: 30844889.
64. Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer 104:188-194, 2018. e-Pub 2018. PMID: 30380460.
65. Flannery K, Cao X, He J, Zhong Y, Shah AY, Kamat AM. Survival Rates and Health Care Costs for Patients with Advanced Bladder Cancer Treated and Untreated with Chemotherapy. Clin Genitourin Cancer 16(4):e909-e917, 2018. e-Pub 2018. PMID: 29735397.
66. Chahoud J, Zhang M, Shah AY, Lin SH, Pisters LL, Tu SM. Managing seminomatous and nonseminomatous germ cell tumors. Curr Opin Oncol 30(3):181-188, 2018. e-Pub 2018. PMID: 29538040.
67. Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int 120(6):782-792, 2017. e-Pub 2016. PMID: 27860149.
68. Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer 17:S1558-7673(17)30238-0, 2017. e-Pub 2017. PMID: 28870517.
69. Malouf GG, Joseph RW, Shah AY, Tannir NM. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol 15(5):409-418, 2017. PMID: 28591094.
70. Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy?. Urol Case Rep 3(2):18-20, 2015. PMID: 26120560.
71. Campbell M, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal P, Varghese J, Shah AY, Long J, Zhang M, Ochineg J, Haymaker C, Habra M. A Phase II Clinical Trial of Cabozantinib Monotherapy for Advanced Adrenocortical Carcinoma. The Lancet Oncology. PMID: None.
72. Johns A, Campbell M, Gao M, Lim Z, Wang E, Hahn AW, Gao J, Shah AY, Masouel P, Tannir N. Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC). None. PMID: None.

Invited Articles

1. Campbell MT, Shah AY. Therapeutic Options for Metastatic Clear Cell Renal Cell Carcinoma: The Front Line and Beyond in Early 2020. ASCO Daily News, 2020. PMID: None.
2. Lemke EA, Shah AY. Choice of Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer. ASCO Clinical Corner, 2018. PMID: None.
3. Nirvana da Cruz-Formiga M, Shah AY. Adjuvant & Neoadjuvant Therapy of Bladder Cancer. Oncology Times, 2017. PMID: None.

Manuals, Teaching Aids, Other Teaching Publications

1. Shah AY. BMJ Best Practice Guidelines: Renal Cell Carcinoma. None, 2017.

Other Articles

1. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. PMID: 38965214.
2. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. PMID: 37072571.
3. Hahn, AW, Shah, AY, Campbell, M First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC). Kidney Cancer 5(4):207-217, 2021. PMID: None.
4. Andreev-Drakhlin AY, Egoryan G, Shah AY, Msaouel P, Alhalabi O, Gao J The Evolving Treatment Landscape of Advanced Urothelial Carcinoma. Curr Opin Oncol 33(3):221-230, 2021. PMID: 33818541.
5. Economides MP, Shah AY, Jimenez C, Habra MA, Desai M, Campbell MT A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Front Endocrinol (Lausanne) 11:594264, 2020. PMID: 33329398.
6. Alhalabi O, Shah AY, Lemke EA, Gao J Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer. Oncology (Williston Park) 33(1):11-8, 2019. PMID: 30731013.
7. Lewis GD, Jonasch E, Shah AY, Fuller GN, Farach AM, Butler EB, Teh BS Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature. Pract Radiat Oncol 8(5):e262-e265, 2018. PMID: 29706304.
8. Lemke EA, Shah AY Management of Advanced Bladder Cancer: An Update. J Adv Pract Oncol 9(4):410-416, 2018. PMID: 30719393.
9. Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO Optimizing management of upper tract urothelial carcinoma. Urol Oncol 35(7):492-498, 2017. PMID: 28579283.
10. Shah AY, Doherty SD, Rosen T Actinic cheilitis: a treatment review. Int J Dermatol 49(11):1225-34, 2010. PMID: 20964646.

Editorials

1. Shah AY, Tannir NM. Surveillance or Systemic Therapy? An Editorial Re: Observation After Cytoreductive Nephrectomy in Patients with Synchronous not Completely Resected Metastases of Renal Cell Carcinoma. Urology 109:132, 2017. PMID: 28867144.
2. Shah AY, Gao J, Siefker-Radtke AO. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy 9(10):781-784, 2017. PMID: 28877627.

Abstracts

1. Xiang JJ, Campbell MT, Tu S, Araujo JC, Nieto Y, Lin JK, Xiao L, Shah AY, Wang J. Doxorubicin, paclitaxel, and cisplatin (ATP) for refractory germ cell tumors. JCO 41(16):None, 2023. e-Pub 2023. PMID: None.
2. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. The Liver Meeting 2022, 2022. PMID: None.
3. Shah AY, Gao J, Rezazadeh A, Cole S, Jain RK, Stevenson A, Fyvie G, Gaw NJ, Pant S. Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy. 2022 ASCO Annual Meeting, 2022. PMID: None.
4. Shah A, Campbell M, Tidwell R, Siefker-Radtke A, GoswamiS, Alhalabi O, Adriazola A, Shaw L, Ye Y, Chen J, Yan X, Wang L, Gao J. A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer. 2022 ASCO Annual Meeting, 2022. PMID: None.
5. Suárez C, Choueiri T, Burotto M, Powles T, Bourlon MT, Shah AY, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Escudier B, Motzer RJ, Apolo A. Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER. 2022 ASCO Annual Meeting, 2022. PMID: None.
6. Singh A, Xiao L, O'Brien BJ, Flowers C, Bruera E, Morris VK, Shah AY. Burnout among early-career medical oncologists: A single-institution experience. 2022 ASCO Annual Meeting, 2022. PMID: None.
7. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Ming S, Jiang Y, Pant S, Shah AY, Zurita A, Tannir N, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib in combination with carboplatin plus paclitaxel in advanced solid malignancies and mTOR pathway alterations. AACR Annual Meeting 2022, 2022. PMID: None.
8. McGregor B, Xie W, Bilen M, Campbell M, Mortazavi A, HuangJ, Sunkara R, Ravi P, Shah A, Baca S, Sonpavde G, Bellmunt J, Siefker-Radtke A, Signoretti S, Van Allen E, Beltran H, McKay R, Choueiri T. Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation. None, 2022. PMID: None.
9. Alhalabi O, Wilson N, Xiao L, Navai N, Kamat A, Shah A, Araujo J, Wang, J, Goswami S, Gao J, Wang J, Guo C, Czerniak B, Corn P, Logothetis C, Dinney C, Campbell M, Tannir N, Siefker-Radtke A. Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC). 2022 ASCO Genitourinary Cancers Symposium, 2022. PMID: None.
10. Alhalabi O, Wilson N, Ajufo H, Lehner M, Hasanov E, Campbell M, Shah A, Wang J, Jonasch E, Araujo J, Wang J, Gao J, Goswami S, Msaouel P, Tannir N. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC). 2022 ASCO Genitourinary Cancers Symposium, 2022. PMID: None.
11. Hahn A, Viscuse P, Surasi D, Bathala T, Wiele A, Starbuck M, Campbell M, Shah A, Jonasch E, Gao J, Alhalabi O, Sircar K, Tannir N, Msaouel P. Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience. 2022 ASCO Genitourinary Cancers Symposium, 2022. PMID: None.
12. McGregor B, Xie W, Bilen M, Campbell M, Mortazavi A, Huang J, Sunkara R, Ravi P, Shah A, Baca S, Sonpavde G, Bellmunt J, Siefker-Radtke A, Signoretti S, Van Allen E, Beltran H, McKay R, Choueiri T. Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation. 2022 ASCO Genitourinary Cancers Symposium, 2022. PMID: None.
13. Shah AY, Powles T, Bourlon MT, Suarez C, Choueiri TK, Motzer RJ, George S, Kessler ER, Bedke J, Escudier B, Zhang J, Simsek B, Scheffold C, Apolo AB, Burotto M. Characterization of responders in the phase 3 CheckMate 9ER trial: nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced renal cell carcinoma. Kidney Cancer Research Summit: KCRS21, 2021. PMID: None.
14. Hahn A, Campbell MT, Shah AY, et al. Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI). ESMO Annual Meeting, 2021. PMID: None.
15. Porta C, Shah AY, et al. First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial. ESMO Annual Meeting, 2021. PMID: None.
16. Shah AY, Motzer RJ, Apolo AB, Powles T, Escudier B, Zhang J, Scheffold C, Karumanchi S, Nguyen LT, Choueirir TK. Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC). American Society of Clinical Oncology, 2021. PMID: None.
17. Lee CH, Shah AY, Hsieh JJ, Rao A, Pinto A, Bilen MA, Cohn AL, DiSimone C, Shaffer DR, Girones-Sarrio R, Ribe SG, W, J, Schmidt EV, Kubiak P, Okpara C, Smith AD, Motzer EJ. Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial. American Society of Clinical Oncology, 2021. PMID: None.
18. Motzer RJ, Choueiri T, Powles T, Burotto M, Bourlon MT, Hsiefh JJ, Maruzzo M, Shah AY, Suarez C, Barrios CH, Richardet ME, Porta C, Goh JC, Tomita Y, Bedke J, ZHang J, Simsek B, Scheffold C, Gupta S, Apolo AB. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. American Society of Clinical Oncology, 2021. PMID: None.
19. Alhalabi O, Wilson N, Navai N, Campbell MT, Shah AY, Gao J, Corn PG, Aparicio A, Czerniak B, Guo C, Logothetis CJ, Tannir NM, Choi S, Siefer-Radtke AO. Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC). American Society of Clinical Oncology, 2021. PMID: None.
20. Apolo AB, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Basso U, Shah AY, Suares C, Porta C, Barrios CH, Gurbey H, Kessler ER, Retz M, George S, Escudier B, Zhang J, Simsek B, Scheffold C, Motzer RJ, Choueiri TK. Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. American Society of Clinical Oncology, 2021. PMID: None.
21. Shah A, Motzer R, Apolo A, Powles T, Escudier B, Zhang J, Scheffold C, Karumanchi S, Nguyen L, Choueiri T. Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC). 2021 ASCO Annual Meeting, 2021. PMID: None.
22. Moore JA, Slack Tidwell R, Campbell MT, Shah AY, Zhang M, Guo C, Ward JF, Karam JA, Wood CG, Logothetis CJ, Pisters LL, Tu SM. Very late recurrence in germ cell tumor of the testis: Lessons and implications. American Society of Clinical Oncology, 2021. PMID: None.
23. Karam J, Msaouel P, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Haymaker CL, Marmonti E, Duose D, Parra ER, Soto LMS, Laberiano C, Lozano M, Abraham A, Hallin M, Olson PD, Der-Torossian HD, Tannir NM, Wood CG. A Phase 2 Study of Sitravatinib (Sitra) in Combination With Nivolumab (Nivo) in Patients (Pts) Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma (accRCC). Journal of Clinical Oncology 39(6):312, 2021. PMID: None.
24. Wilson N, Wiele AJ, Surasi DS, Rao P, Sircar K, Shah AY, Genovese G, Karam A, Wood CG, Tannir M, Msaouel P. Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC). American Society of Clinical Oncology, GU Symposium, 2021. PMID: None.
25. Andreev-Drakhlin AY, Shah AY, Andriazola A, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Goswami S, Xiao L, Venkatesan AM, Campbell MT. Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). Journal of Clinical Oncology 39(6):487, 2021. PMID: None.
26. Wiele AJ, Surasi DS, Rao P, Sircar K, Bathala T, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam J, Wood CG, Tannir M, Msaouel P. The efficacy of bevacizumab plus erlotinib (B+E) in patients (pts) with renal medullary carcinoma (RMC). American Society of Clinical Oncology, GU Symposium, 2021. PMID: None.
27. Msaouel P, Gao J, Yuan Y, Siefker-Radtke A, Jonasch E, Goswami S, Zurita AJ, Campbell MT, Shah AY, Corn PG, Ramos C, Yan X, Chin C, Der-Torossian H, Tannir N. Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies. American Society of Clinical Oncology, GU Symposium, 2021. PMID: None.
28. Motzer RJ, Choueiri T, Powles T, Burotto M, Bourlon MT, Hsiefh JJ, Maruzzo M, Shah AY, Suarez C, Barrios CH, Richardet ME, Porta C, Goh JC, Tomita Y, Bedke J, ZHang J, Simsek B, Scheffold C, Gupta S, Apolo AB. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. American Society of Clinical Oncology, GU Symposium, 2021. PMID: None.
29. Yibirin M, Pundhir P, Yepez-Guevara E, Granwehr BP, Kaseb A, Patel S, Naing A, Shah AY, Skoulidis F, Tawbi HA, Zhang HC, Wang L, Miller E, Torres HA. Safety of Immune Checkpoint Inhibitors in Cancer Patients with Chronic Hepatitis C Infection: A Prospective Observational Study. The Liver Meeting 2020, 2020. PMID: None.
30. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood C, Tannir, N, Jonasch E, Gao JJ, Zurita A, Shah AY, Blando J, Duan F, Basu S, Yadav SS, Allison JP, Sharma P. A pilot study of Tremelimumab with or without cryoablation in patients with metastatic renal cell carcinoma (mRCC): a post hoc analysis of patients with clear cell (cc) versus non-clear cell (ncc) histologies. IKCS, 2020. PMID: None.
31. Alhalabi O, Hahn A, Msaouel P, Meric-Bernstam F, Naing A, Piha-Paul S, Janku F, Pant S, Yap T, Hong D, Fu S, Karp D, Campbell E, Campbell M, Shah A, Tannir N, Siefker-Radtke A, Gao J, J Roszik J, Subbiah V. Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials. ESMO Congress 2020, 2020. PMID: None.
32. Siddiqui B, Gheeya J, Goswamy R, Subudhi S, Gao J, Campbell M, Shah A, Msaouel P, Zurita-Saavedra A, Goswami S, Wang J, Jonasch E, Siefker-Radtke A, Sharma P, Tannir N. Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC). 2020 ESMO Congress, 2020. PMID: None.
33. Zou F, Shah AY, Glitza I, Richards D, Thomas A, Wang Y. Comparative Study of Vedolizumab and Infliximab Treatment in Patients with Immune-mediated Diarrhea and Colitis. ACG, 2020. PMID: None.
34. Lee C, Shah AY, Hsieh J, Rao A, Pinto A, Bilen M, Cohn A, Simone C, Shaffer D, Sarrio R, Ribe S, Wu J, Schmidt E, Ri P, Kubiak P, Smith A, Motzer R. Phase 2 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). American Society of Clinical Oncology, 2020. PMID: None.
35. Msaouel P, Van Alstine M, Oromendia C, Gao J, Wang Y, Siddiqui B, Siefker-Radtke A, Shah AY, Shaw L, Lopez L, Laccetti A, Tannir NM, Elashoff M, Logothetis CJ. Technology-Enabled Longitudinal Monitoring of patient-reported outcomes (PROs) to individualize care of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ICIs). American Society of Clinical Oncology, 2020. PMID: None.
36. McGregor B, Campbell MT, Xie W, Farah S, Bilen M, Sonpavde G, Kilbridge K, Choudhury A, Mortazavi A, Shah AY, Venkatesan A, Bubley G, Siefker-Radtke A, McKay R, Choueiri T. Phase II study of Nivolumab and Ipilimumab for advanced rare genitourinary cancers. American Society of Clinical Oncology, 2020. PMID: None.
37. Alhalabi O, Chen J, Campbell MT, Ramachandran S, Tidwell R, Shah AY, Wang W, Efstathiou E, Hoang A, Siefker-Radtke A, Msaouel P, Zhang M, Guo C, Czerniak B, Titus M, Logothetis C, Ho T, Wang L, Gao J. Clinical efficacy and metabolite biomarker analysis of patients with MTAP-deficient urothelial carcinoma treated with anti-folates. American Society of Clinical Oncology, 2020. PMID: None.
38. Alhalabi O, Hahn A, Meric-Bernstam F, Naing A, Piha-Paul S, Janku F, Pant S, Yap T, Hong D, Fu S, Campbell E, Le E, Shah AY, Campbell MT, Tannir N, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials. American Society of Clinical Oncology, 2020. PMID: None.
39. Garmezy B, Zhang T, Laccetti A, Economides M, Shah AY, Tannir NM, Jonasch E, Msaouel P, Zurita AJ, Corn PG, Venkatesan AM, Brown LC, Kao C, Kinsey EN, Harrison MR, Armstrong AJ, George DJ, Campbell MT. Combination Therapy with Nivolumab and Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology, 2020. PMID: None.
40. Msaouel P, Thall PF, Yuan Y, Wang X, Jonasch E, Gao JJ, Campbell MT, Shah AY, Corn PG, Tam A, Ahrar K, Rao P, Sircar K, Der-Torossian H, Tannir N. A phase I/II trial of sitravantinub combined with nivolumab in patients with advanced clear cell renal cell cancer that progressed on prior VEGF- targeted therapy. Journal of Clinical Oncology 38(6):612, 2020. PMID: None.
41. Tayar J, Suarez-Almazor M, Lu H, Zhao Y, Divenko M, Padron W, Rodriguez E, Neelapu S, Wang J, Shah AY, Tannir N, Gibbons D, Garcia-Manero G, Tawbi H, Hwu P, Futreal A, Diab A, Nurieva R. Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy. ACR Convergence 2020, 2020. PMID: None.
42. Shah AY, et al. Phase 2 study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): results of an interim analysis. Kidney Cancer Association, 18th International Kidney Cancer Symposium, 2019. PMID: None.
43. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood C, Tannir, N, Jonasch E, Gao JJ, Zurita A, Shah AY, Blando J, Duan F, Basu S, Yadav SS, Allison JP, Sharma P. A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)). Annals of Oncology 30(5):V3089-390, 2019. PMID: None.
44. Matulay JT, Campbell MT, Narayan VM, Seif MA, Lim AH, Shah AY, Pavlos M, Gao JJ, Siefker-Radtke AO, Dinnery CPN, Kamat AM, Navai N. Pathologic Outcomes after Neoadjuvant Chemotherapy for High-risk Muscle Invasive Bladder Cancer. Annals of Oncology 30(5):V370, 2019. PMID: None.
45. Lee CH, Shah AY, Makker V, Taylor M, Shaffer D, Hsieh J, Cohn A, DiSimone C, Marin, AP, Ribe SG, Richards DA, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Perini R, Motzer R. Phase 2 study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): results of an interim analysis. European Society for Medical Oncology 30(5):V475-V532, 2019. PMID: None.
46. Siddiqui BA, Durand JB, Gao J, Wang J, Aparicio A, Campbell MT, Siefkfer-Radtke AO, Tannir NM, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu SM, Suarez-Almazor ME, Sudhakar T, Logothetis CJ, Sharma P, Subudhi SK. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. American Society of Clinical Oncology, 2019. PMID: None.
47. Pant S, Mulder I, Shah AY, Msaouel P, Altan M, Weinberg J, Stevenson A, Meric-Bernstam F, Yap TA, Subbiah V, Ahnet JR. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. American Society of Clinical Oncology, 2019. PMID: None.
48. McGregor BA, Campbell MT, Xie W, Siefker-Radtke A, Shah AY, Venkatesan AM, Kilbridge KL, Sonpavde G, Bubley G, McKay RR, Choueiei TK. Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH). American Society of Clinical Oncology, 2019. PMID: None.
49. Gao J, Karam JA, Tannir NM, Campbell MT, Slack Tidwell R, Ahrar K, Rao P, Ng CS, Jonasch E, Matin SE, Zurita AH, Shah AY, Shen Y, Blando JM, Vence LM, Basu S, Zhao H, Allison JP, Wood CG, Sharma P. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). American Society of Clinical Oncology, 2019. PMID: None.
50. Gao J, Siekfer-Radtke AO, Navai N, Campbell MT, Slack Tidwell R, Guo C, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Allison JP, Dinney CP, Sharma P. A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). American Society of Clinical Oncology, 2019. PMID: None.
51. Campbell MT, Xie W, Shah AY, Habra MA, Jimenez C, Venkatesan A, Killbridge KL, Bubley G, Mortazavi A, Bilen MA, McKay R, Choueiri TK, McGregor BA. Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastaic Adrenal Tumors. Annals of Oncology 30(5):V500, 2019. PMID: None.
52. Laccetti AL, Economides MP, Venkatesean AM, Gao J, Jonasch E, Corn PG, Zurita AJ, Tannir NM, Msaouel P, Shah AY, Campbell MT. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. American Society of Clinical Oncology, GU Symposium, 2019. PMID: None.
53. Alhalabi O, Campbell MT, Slack-Tidwell R, Siefker-Radtke AO, Shah AY, Efstathiou E, Wang WL, Titus MA, Czerniak B, Zhang M, Guo C, Logothetis CJ, Gao J. A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma. American Society of Clinical Oncology, GU Symposium(37):7s, 2019. PMID: None.
54. Choi S, Campbell MT, Shah AY, Navai N, Kamat AM, Dinney C, Nguyen Q, Siefker-Radtke AO. Prophylactic cranial irradiation (PCI) significantly decreases risk of brain metastases in patients with bulky, higher stage small-cell urothelial cancer. American Society of Clinical Oncology, GU Symposium(37):7s, 2019. PMID: None.
55. Shah AY, Lemke E, Gao J, Chandramohan A, Campbell MT, Zurita AJ, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NMhah A, Lemke E, Gao J, Chandramohan A, Campbell MT, Zurita AJ, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. American Society of Clinical Oncology, GU Symposium(37):7s, 2019. PMID: None.
56. Kim ST, Tayar JH, Suarez-Almazor M, Lu H, Zhao YZ, Liu Z, Rodriguez EE, Neelapu SS, Wang J, Shah AY, Tannir NM, Gibbons DL, Garcia-Manero G, Tawbi H, Hwu P, Futreal A, Diab A, Nurieva R. Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy. 2019 ACR/ARP Annual Meeting, 2019. PMID: None.
57. Shah AY, et al. What are the best agents for second line and beyond in the treatment of metastatic clear cell renal cell carcinoma?. Kidney Cancer Association, 17th International Kidney Cancer Symposium, 2018. PMID: None.
58. Ross JA, McCormick BZ, Gao J, Msaouel P, Campbell MT, Zurita AJ, Shah SY, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) and sarcomatoid dedifferentiation (sRCC) after treatment with immune checkpoint inhibitors (ICI): A single-institution retrospective study. American Society of Clinical Oncology, 2018. PMID: None.
59. Campbell MT, Lemke EA, Elsayes KM, Bazerbashi B, Shah AY, Habra MA. A retrospective analysis of carboplatin plus etoposide in patients with adrenal cortical carcinoma. American Society of Clinical Oncology, 2018. PMID: None.
60. Choueiri TK, Apolo AB, Escudier B, Aren OR, Shah AY, Kessler ER, Hsieh JJ, gJ Z, Simsek B, Scheffold C, Motzer RJ. A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). American Society of Clinical Oncology, 2018. PMID: None.
61. Gao J, Siefker-Radtke AO, Navai N, Campbell MT, Slack Tidwell R, Guo C, Kamat AM, Matin SF, Papadopoulos JN, Araujo JC, Shah AY, Blank JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Dinney CP, Sharma P. A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy. American Society of Clinical Oncology, 2018. PMID: None.
62. Chahoud J, Campbell MT, Gao J, Zurita AJ, Shay AY, Msaouel P, Ross JA, Xiao L, Jonasch E, Sharma P, Tannir NM. Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience. American Society of Clinical Oncology, 2018. PMID: None.
63. Lemke EA, Shah AY, Msaouel P, Bilen MA, Jonasch E, Venkatesan AM, Chandamohan A, Duran C, Tannir NM, Campbell MT. Comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC): A retrospective study. American Society of Clinical Oncology, GU Symposium, 2018. PMID: None.
64. Lemke EA, Shah AY, Chandramohan A, Campbell MT, Van Alstine M, Jonasch E, Tannir NM. Real-world experience with cabozantinib in metastatic clear cell renal cell carcinoma (mccRCC). American Society of Clinical Oncology, GU Symposium, 2018. PMID: None.
65. Shah AY, Lemke EA, Gao J, Chandamohan A, Campbell MT, Zurita A, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir N. Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI). American Society of Clinical Oncology, GU Symposium, 2018. PMID: None.
66. Shay AY, Lemke EA, Gao J, Chandramohan A, Campbell MT, Zurita AJ, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy. European Society for Medical Oncology 28(5):V295-329, 2017. PMID: None.
67. Shah AY, Karam JA, Malouf GG, Lim ZD, Jonasch E, Xioao L, Gao J, Vaisham payan UN, Chin Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin AF, Rathmell K, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients. American Society of Clinical Oncology, 2016. PMID: None.
68. Campbell MT, Shah AY, Nautiyal KD, Hashemi N, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Association of chronic co-morbidities with long term survival with metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology, GU Symposium 33(7):472, 2015. PMID: None.
69. Campbell M, Shah AY, Tannir NM. Characterization of Long-term Survivors of Metastatic RCC: Prognostics and Duration of Response in Era of Targeted Therapy. American Society of Clinical Oncology, GU Symposium, 2015. PMID: None.
70. Campbell MT, Shah AY, Hashemi N, Nautiyal KD, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Long-term survivorship in patients (pts) with metastatic renal cell cancer (mRCC): A retrospective study from the MD Anderson Cancer Center (MDACC). American Society of Clinical Oncology, GU Symposium 33(7):510, 2015. PMID: None.
71. Shah AY, Campbell MT, Nautiyal KD, Hashemi N, Matin SF, Vaporciyan AA, Rhines LD, Moon B, Lewis VO, Lin PP, Prabhu SS, Rao G, Corn PG, Pagliaro LC, Mehran RJ, Wood CJ, Jonasch E, Tannir NM. Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC). American Society of Clinical Oncology, GU Symposium 33(7):504, 2015. PMID: None.
72. Campbell M, Shah AY, et al TN. Review of Toxicities in Long-term Survivors of Metastatic RCC. Amerian Society of Clinical Oncology, GU Symposium, 2015. PMID: None.
73. Shah AY, Karam JA, Rao P, Jonasch E, Rathmell K, Matin SF, Vaishampayan UN, Heng D, Plimack ER, Guancial EA, Fung C, Lowas SR, Lim ZD, Wood CG, Tannir NM. Management and Outcomes of Patients with Renal Medullary Carcinoma (RMC): A Multi-Center Retrospective Study of 39 patients. American Society of Clinical Oncology, GU Symposium, 2015. PMID: None.
74. Shah AY, Motiwala S, Brose MS, O'Dwyer PJ, Flaherty K, Keefe SM. Increase in blood pressure with sorafenib exposure: Renal cell carcinoma (RCC) versus other solid tumors. American Society of Clinical Oncology, 2013. PMID: None.
75. Shah AY, Motiwala S, O'Dwyer PJ, Flaherty KT, Keefe SM. Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. American Society of Clinical Oncology, GU Symposium, 2013. PMID: None.
76. Shah AY, Brose M, Haas N, Vaughn D, Flaherty K, O'Dwyer P, Keefe SM. Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. American Medical Association, 2012. PMID: None.

Book Chapters

1. Ravindranathan, D, Alhalabi, O, Rafei, H, Shah, AY, Bilen, MA. Landscape of Immunotherapy in Genitourinary Malignancies, 143-192, 2021.
2. Alhalabi O, Rafei H, Bilen M, Shah, AY. Current Landscape of Immunotherapy in Genitourinary Malignancies. In: Adv Exp Med Biol. None. None, 2020.